These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16973247)

  • 1. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
    Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
    Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
    Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
    Klinman DM; Xie H; Little SF; Currie D; Ivins BE
    Vaccine; 2004 Jul; 22(21-22):2881-6. PubMed ID: 15246624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
    Berthold I; Pombo ML; Wagner L; Arciniega JL
    Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
    Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
    Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
    Klinman DM; Xie H; Ivins BE
    Ann N Y Acad Sci; 2006 Oct; 1082():137-50. PubMed ID: 17145935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an in vitro-based potency assay for anthrax vaccine.
    Little SF; Webster WM; Ivins BE; Fellows PF; Norris SL; Andrews GP
    Vaccine; 2004 Jul; 22(21-22):2843-52. PubMed ID: 15246620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
    Klinman DM
    Expert Rev Vaccines; 2006 Jun; 5(3):365-9. PubMed ID: 16827620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
    Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
    Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.
    Pittman PR; Norris SL; Barrera Oro JG; Bedwell D; Cannon TL; McKee KT
    Vaccine; 2006 Apr; 24(17):3654-60. PubMed ID: 16497418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
    Sloat BR; Cui Z
    Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
    Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
    Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
    Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
    Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.